Cargando…

Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?

SIMPLE SUMMARY: Epigenetic events, which comprise post-translational modifications of histone tails or DNA methylation, control gene expression by altering chromatin structure without change in the DNA sequence. Histone tails modifications are driven by specific cellular enzymes such as histone meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Krossa, Imène, Strub, Thomas, Aplin, Andrew E., Ballotti, Robert, Bertolotto, Corine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563040/
https://www.ncbi.nlm.nih.gov/pubmed/36230787
http://dx.doi.org/10.3390/cancers14194865
_version_ 1784808312761483264
author Krossa, Imène
Strub, Thomas
Aplin, Andrew E.
Ballotti, Robert
Bertolotto, Corine
author_facet Krossa, Imène
Strub, Thomas
Aplin, Andrew E.
Ballotti, Robert
Bertolotto, Corine
author_sort Krossa, Imène
collection PubMed
description SIMPLE SUMMARY: Epigenetic events, which comprise post-translational modifications of histone tails or DNA methylation, control gene expression by altering chromatin structure without change in the DNA sequence. Histone tails modifications are driven by specific cellular enzymes such as histone methyltransferases or histone acetylases, which play a key role in regulating diverse biological processes. Their alteration may have consequences on growth and tumorigenesis. ABSTRACT: Epigenetic regulations, that comprise histone modifications and DNA methylation, are essential to processes as diverse as development and cancer. Among the histone post-translational modifications, lysine methylation represents one of the most important dynamic marks. Here, we focused on methyltransferases of the nuclear binding SET domain 1 (NSD) family, that catalyze the mono- and di-methylation of histone H3 lysine 36. We review the loss of function mutations of NSD1 in humans that are the main cause of SOTOS syndrome, a disease associated with an increased risk of developing cancer. We then report the role of NSD1 in triggering tumor suppressive or promoter functions according to the tissue context and we discuss the role of NSD1 in melanoma. Finally, we examine the ongoing efforts to target NSD1 signaling in cancers.
format Online
Article
Text
id pubmed-9563040
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95630402022-10-15 Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma? Krossa, Imène Strub, Thomas Aplin, Andrew E. Ballotti, Robert Bertolotto, Corine Cancers (Basel) Review SIMPLE SUMMARY: Epigenetic events, which comprise post-translational modifications of histone tails or DNA methylation, control gene expression by altering chromatin structure without change in the DNA sequence. Histone tails modifications are driven by specific cellular enzymes such as histone methyltransferases or histone acetylases, which play a key role in regulating diverse biological processes. Their alteration may have consequences on growth and tumorigenesis. ABSTRACT: Epigenetic regulations, that comprise histone modifications and DNA methylation, are essential to processes as diverse as development and cancer. Among the histone post-translational modifications, lysine methylation represents one of the most important dynamic marks. Here, we focused on methyltransferases of the nuclear binding SET domain 1 (NSD) family, that catalyze the mono- and di-methylation of histone H3 lysine 36. We review the loss of function mutations of NSD1 in humans that are the main cause of SOTOS syndrome, a disease associated with an increased risk of developing cancer. We then report the role of NSD1 in triggering tumor suppressive or promoter functions according to the tissue context and we discuss the role of NSD1 in melanoma. Finally, we examine the ongoing efforts to target NSD1 signaling in cancers. MDPI 2022-10-05 /pmc/articles/PMC9563040/ /pubmed/36230787 http://dx.doi.org/10.3390/cancers14194865 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Krossa, Imène
Strub, Thomas
Aplin, Andrew E.
Ballotti, Robert
Bertolotto, Corine
Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?
title Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?
title_full Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?
title_fullStr Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?
title_full_unstemmed Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?
title_short Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?
title_sort lysine methyltransferase nsd1 and cancers: any role in melanoma?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563040/
https://www.ncbi.nlm.nih.gov/pubmed/36230787
http://dx.doi.org/10.3390/cancers14194865
work_keys_str_mv AT krossaimene lysinemethyltransferasensd1andcancersanyroleinmelanoma
AT strubthomas lysinemethyltransferasensd1andcancersanyroleinmelanoma
AT aplinandrewe lysinemethyltransferasensd1andcancersanyroleinmelanoma
AT ballottirobert lysinemethyltransferasensd1andcancersanyroleinmelanoma
AT bertolottocorine lysinemethyltransferasensd1andcancersanyroleinmelanoma